Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)J. Jean Cui, Martin P. Edwards, Michelle Tran‐Dubé et al.|Journal of Medicinal Chemistry|2011Cited by 924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsTed W. Johnson, Martin P. Edwards, John C. Kath et al.|Journal of Medicinal Chemistry|2014Cited by 587
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to CrizotinibQinhua Huang, Martin P. Edwards, Ted W. Johnson et al.|Journal of Medicinal Chemistry|2014Cited by 118
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1Rebecca A. Gallego, Sajiv K. Nair, Louise Bernier et al.|Journal of Medicinal Chemistry|2023Cited by 37
Case HistoryJ. Jean Cui, Martin P. Edwards, Michele McTigue et al.|Annual reports in medicinal chemistry|2013Cited by 23